Johnson & Johnson Makes Grand Debut at the 6th CIIE with Over 100 Innovative Products Following Brand Refresh

ShanghaiOctober 28, 2023PR Newswire -- The much-anticipated 6th China International Import Expo (CIIE) is about to open. This year, Johnson & Johnson will participate in the CIIE for the sixth consecutive year, showcasing over a hundred innovative products from its medical technology and innovative pharmaceuticals businesses, nearly one-third of which will make their debut in China or even globally. As a six-time CIIE "veteran," this year will also mark Johnson & Johnson's CIIE "debut" following the spin-off of its consumer health business and brand renewal.

This year, under the theme of "Johnson & Johnson: Renewing Health for a Brighter Future," Johnson & Johnson will unveil its refreshed brand image at the Medical Devices and Healthcare Products Exhibition Area in Hall 7.2 of the National Exhibition and Convention Center (China). The Johnson & Johnson booth is divided into three main thematic zones. The brand renewal zone showcases the company’s revitalized corporate logo, featuring a vibrant red-and-white color scheme and a modern, minimalist design that conveys Johnson & Johnson's warmth and care for life, rapid response to health challenges, acceleration of healthcare innovation, and ambition to continuously lead industry development. In the innovative products zone and social impact zone, Johnson & Johnson highlights its achievements in healthcare innovation under the two key themes of "Innovation for a Healthy China" and "Credo-Guided Commitment to Social Responsibility," demonstrating its contributions and positive impact on society.

Johnson & Johnson Debuts with Medical Technology and Innovative Pharmaceuticals at the Sixth CIIE

Hardcore medical and health innovation products and solutions have always been the highlight of Johnson & Johnson's participation in the CIIE. This year, Johnson & Johnson is participating for the first time with a focus on its two major businesses: medical technology and innovative pharmaceuticals. It is showcasing over a hundred innovative products across various disease areas, including surgery, cardiovascular and cerebrovascular diseases, high-incidence cancers, orthopedics, eye health, immunology, mental health, infectious diseases, and rare diseases. This comprehensive display demonstrates Johnson & Johnson’s commitment to addressing severe health challenges with its cross-business capabilities, as well as its dedication to supporting "Healthy China" while firmly establishing itself in China.

Supported by the strong spillover effects of the CIIE, several star exhibits from previous China International Import Expos (CIIE) by Johnson & Johnson have been accelerated to market more quickly, serving patient needs. These will now return to the CIIE as commercial products. Johnson & Johnson Medical Technologies MONARCH^TMThe natural orifice diagnosis and treatment robotic surgery platform made its Asian debut at the CIIE, offering smarter, less invasive, and more personalized surgical solutions through digital technology innovation; DARZALEX FASPRO® (subcutaneous injection of daratumumab), a drug under Johnson & Johnson’s innovative pharmaceutical division, will not only fill the treatment gap for the rare disease light chain amyloidosis but also mark another significant milestone in accelerating services for Chinese patients with multiple myeloma.

Moreover, nearly one-third of the exhibits at Johnson & Johnson's booth this year are debut products. Johnson & Johnson Medical Technologies showcased nearly 30 debut products, including the global premiere of the STSF DE Pulse/RF Dual-Energy Catheter, the China premiere of the new antibacterial upgraded solution Monocryl® Plus and the upgraded antibacterial product PDS® Plus - GAMMA, the MATRIXWAVE™ MMF SYSTEM for intermaxillary fixation, the world’s first purely refractive presbyopia-correcting EDOF intraocular lens TECNIS PureSee™ IOL, and the ACUVUE® OASYS MAX 1-Day daily disposable contact lenses.

Johnson & Johnson's innovative pharmaceuticals business is presenting two innovative products in the field of multiple myeloma for the first time in China, including the T-cell redirecting bispecific antibody Talvey™ (Talquetamab) and the fully humanized T-cell redirecting bispecific antibody TECVAYLI™ (Teclistamab), offering more innovative treatment options for patients with multiple myeloma.

This year marks the 80th anniversary of Johnson & Johnson's "Our Credo," which outlines the company’s responsibilities to patients, customers, employees, society, and shareholders, serving as a guiding compass for Johnson & Johnson. To commemorate this historic milestone, Johnson & Johnson will establish a social impact exhibition area at its CIIE booth to showcase the company’s abundant achievements in improving human health and well-being and giving back to society through innovation. Over the years, while accelerating the introduction of globally leading innovative products, Johnson & Johnson has continuously enhanced the accessibility and affordability of high-quality healthcare resources; supported professional empowerment for healthcare workers, promoting high-quality development in the healthcare industry; actively fostered a diverse and inclusive corporate culture, advancing employer branding and talent development; fulfilled corporate social responsibility, building environmental health, achieving green development, and supporting public welfare to contribute to economic and social progress.

Song Weiqun, Global Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China, stated: "The CIIE is an important platform for China to promote high-level opening up and high-quality development. Johnson & Johnson has participated in six consecutive editions of the CIIE, reaping abundant rewards. This year, we can say that we are both a ‘long-time friend’ and a ‘new face’ at the CIIE. The ‘magnetic effect’ of previous CIIEs has allowed us to feel the new vitality of the Chinese economy under high-level openness, further strengthening our confidence in Johnson & Johnson’s long-term commitment to the Chinese market. We will deepen innovative cooperation with all parties and jointly contribute to the high-quality development of China's healthcare industry. Making our debut at the CIIE during the Johnson & Johnson brand renewal marks a powerful step into a new era, initiating a new chapter in healthcare in the Chinese market. We look forward to gathering with everyone at the CIIE, continuing this exciting journey, and jointly creating a healthier future!"